7 June 2024
Graft Polymer (UK)
Plc
(the
"Company")
Update on Recent
Developments
Graft Polymer (UK) Plc (LSE: GPL),
an innovative developer of biopolymer drug delivery systems aimed
at enhancing the effectiveness of therapeutics for
biopharmaceutical companies, is pleased to provide an overview of
recent progress.
Operational Review
On 2 May 2023, the Company announced
the initiation of an operational review. The Company is pleased to
report that the first phase of this review has concluded. Moving
forward, one focus area for the Company will be to seek commercial
opportunities for its patented self-nanoemulsifying drug delivery
systems (SNEDDS) platform, to enhance the bioavailability,
pharmacokinetics, and stability of biopharmaceutical companies'
therapeutics.
Currently, the Company is evaluating
a shortlist of five entities for potential future commercial
collaboration in this space.
Focus on the Healthcare Industry
On 3 May 2024, the Company disclosed
the disposal of Graft Polymer d.o.o., allowing us to concentrate
our attention and resources on our Graft Bio division. The
Directors believe this division holds significant potential due to
its intellectual property (IP), licensing agreements, and sales
contracts.
Recent Patent Filings
The Company continues to develop its
intellectual property portfolio, supporting its focus on the
healthcare industry clients and targeting SNEDDS-related commercial
collaboration opportunities. Recently, the Company submitted two
utility patent applications (provisional) to the United States
Patent and Trademark Office (USPTO) for using its SNEDDS platform
in drug delivery for substance use disorders and mental health
treatment.
On 28 May 2024, the Company filed
the first of these applications titled "Composition and Methods for
Substance Use Disorders (SUDS) using a Self-Nanoemulsifying Drug
Delivery System (SNEDDS)," covering the innovative application of
its SNEDDS platform to enhance the bioavailability,
pharmacokinetics, and stability of therapeutics used in treating
substance use disorders.
On 31 May 2024, the Company filed
the second provisional patent titled "Composition and Methods for
Mental Health Disorders using a Self-Nanoemulsifying Drug Delivery
System (SNEDDS)," covering the innovative application of our SNEDDS
platform to enhance the bioavailability, pharmacokinetics, and
stability of therapeutics used in treating mental health disorders
such as Generalized Anxiety Disorder (GAD), Major Depressive
Disorder (MDD), and Post-Traumatic Stress Disorder
(PTSD).
Enquiries:
Graft Polymer (UK) Plc:
Anthony Tennyson, CEO and Executive
Director: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive
Director: yifat@graftpolymer.com
Allenby Capital (Broker):
Phone: +44 (0) 20 3328
5656
Nick Naylor / Liz Kirchner
(Corporate Finance)
Guy McDougall (Sales)
About Graft Polymer (UK) Plc
Graft Polymer (UK) Plc (LSE: GPL) is
an innovative developer of biopolymer drug delivery systems
dedicated to assisting biopharmaceutical companies in enhancing the
effectiveness of their therapeutics. Our proprietary patented
platform, a bioabsorbable self-nanoemulsifying drug delivery system
(SNEDDS), represents a cutting-edge solution in drug delivery
technology. By integrating active pharmaceutical ingredients (APIs)
into our novel, patented delivery systems, we enable clients to
improve the bioavailability, pharmacokinetics, and stability of
their therapeutics.
